Reciprocal relationship from LLY graph: 8,190.0 $ 14,667.5 $ 12,333.1 $ 10,351.3 Numbers may not add due to rounding. (1) Jardiance revenue includes Glyxambi, Synjardy, and Trijardy XR. (2) Humalog r…
Reciprocal relationship from PRME graph: orm is expected to allow Prime Medicine to generate follow-on candidates rapidly and efficiently. In addition, we are identifying partnership opportunities to…
Reciprocal relationship from SANA graph: Reciprocal relationship from BEAM graph: Reciprocal relationship from SANA graph: Reciprocal relationship from BEAM graph: Reciprocal relationship from SANA g…
Reciprocal relationship from SANA graph: the University of California (UCSF), our fusogen technology that we acquired from Cobalt Biomedicine, Inc. (Cobalt), and gene editing technology that we licen…
Beam Therapeutics Inc. Debt Obligations
Instrument
Description
Confidence
Evidence
BEAM-DEBT-8131
Xbrl Convertible
90%
xbrl convertible detail from xbrl 2020-12-31.
BEAM-DEBT
Debt stack $250.8M
90%
Market cache reports total debt of $250.8M.
Beam Therapeutics Inc. Acquisitions
No acquisitions on recordNo completed or pending acquisitions found in our database for Beam Therapeutics Inc..
Beam Therapeutics Inc. Ownership
Holder
Name
Confidence
Evidence
BEAM-OWNER-FMR-LLC
FMR LLC
90%
13F overlay lists FMR LLC as top holder; 254 tracked holders.
Beam Therapeutics Inc. Extended Supply Chain Network